A Phase 3 interventional study of Apllication of medical device ice pack and Apllication of cream in Chronic Respiratory Diseases, sponsored by University Hospital, Brest. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by University Hospital, Brest · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pain by University Hospital, Brest — 2 open to participants now, 2 under way, 1 of them phase 3. Pain · University Hospital, Brest.
Among the 11 studies in Pain by University Hospital, Brest, this one is the only one that started in 2026, is one of 2 in phase 3, and was the 11th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →2 of the 11 studies in Pain by University Hospital, Brest are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Brest · Sites in France
Ages up to 24
By country, each count listing its studies:
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 258 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 60 across the 8 interventional studies, 60 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Brest is the lead sponsor of 602 studies on the registry; 137 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Pain by University Hospital, Brest, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Arterial puncture for blood gas analysis is a diagnostic procedure used to assess arterial blood gases and monitor a patient's oxygenation status. It is widely regarded by nursing staff as one of the most painful routine procedures. Despite this, the use of local anesthesia prior to arterial puncture remains uncommon in clinical practice.
Several types of anesthetic agents and administration techniques have been evaluated, with mixed results regarding their effectiveness in reducing patient-reported pain. Studies comparing subcutaneous lidocaine injection or ethyl chloride spray to no analgesic intervention have shown that ethyl chloride does not significantly reduce pain. Moreover, the discomfort caused by lidocaine injection appears to be comparable to that of the arterial puncture itself, suggesting limited overall benefit from this approach.
Other investigations have similarly reported a lack of significant pain reduction with ethyl chloride spray, although some contradictory findings exist. Ultrasound-guided arterial puncture has been shown to improve success rates and shorten procedure duration; however, it does not appear to influence pain perception.
The impact of needle size on pain intensity has also been explored, with conflicting results. Some studies found no significant difference in pain when using different gauge needles, while others reported reduced pain with the use of finer needles, such as insulin needles, compared to standard arterial puncture needles.
Topical anesthetic creams combining lidocaine and prilocaine have been assessed in randomized, double-blind trials. These studies found no significant difference between anesthetic and placebo groups in terms of pain intensity or the proportion of painful procedures.
More recently, cryotherapy has been investigated as a non-pharmacological method to reduce pain prior to arterial puncture. Several randomized controlled trials using varying cryotherapy protocols have generally reported a significant reduction in pain compared to control groups, with longer application times appearing to enhance effectiveness.
However, these findings must be interpreted with caution due to methodological limitations. In some studies, sample size calculations were not justified, randomization procedures were poorly described, and reported pain levels were unusually high compared to those typically observed in European populations, raising concerns about external validity. In certain cases, although pain reduction was statistically significant, it did not reach the minimal clinically important difference, limiting its clinical relevance.
Conversely, other trials reported very low pain scores following cryotherapy, suggesting a substantial clinical benefit. The short application time required for cryotherapy also makes it far more practical than topical anesthetic creams, which require prolonged application. This practicality supports its use in both emergency and outpatient settings.
Some authors have noted that blinding is challenging when using cryotherapy and have suggested incorporating placebo interventions in future studies to improve methodological rigor.
Overall, systematic analyses indicate that cryotherapy appears to be a safe and potentially effective method for reducing pain during arterial puncture. Nevertheless, the existing evidence is limited by a high risk of bias, underscoring the need for further high-quality randomized controlled trials.
Conclusion: Given the promising but methodologically constrained evidence, there is a strong justification for conducting a rigorously designed, placebo-controlled randomized trial to accurately assess the effectiveness of cryotherapy in reducing pain associated with radial arterial puncture.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Application of a medical ice pack on the arm prior to the arterial blood gas procedure
Device: Apllication of medical device ice pack
Application of placebo cream on the arm prior the arterial blood gas procedure
Drug: Apllication of cream
Application of lidocaine cream on the arm prior arterial blood gas procedure
Drug: Apllication of cream
Application of a medical device pack during 3 minutes on the area where the arterial blood gas will be performed.
Application of a cream 120 min before on the area where the arterial blood gas will be performed.
Pain, measured on a 0-10 numerical rating scale
The Pain experienced during the arterial puncture will be measured with the 0-10 numerical rating scale ( : 0 = no pain, and 10 = the worse pain)
Time frame: Periprocedural
Situational anxiety, measured with the STAI-Y state scale
The situational anxiety experienced just before the arterial puncture (i.e. 3 minutes after cryotherapy or 2 hours after cream application) will be measured with the STAI-Y state scale (ranging from 20 to 80, with higher score correlating with greater anxiety)
Time frame: 3 minutes after cryotherapy or 2 hours after cream application]
Situational anxiety measured by the heart rate
The situational anxiety experienced just before the arterial puncture (i.e. 3 minutes after cryotherapy or 2 hours after cream application) will be measured by the heart rate in beat per minute with a pulse oxymeter
Time frame: 3 minutes after cryotherapy or 2 hours after cream application
Situational anxiety measured by the heart rate
The situational anxiety experienced during the arterial puncture will be measured by the heart rate in beat per minute with a pulse oxymeter
Time frame: Periprocedural
Situational anxiety measured by the heart rate
The situational anxiety experienced at the end of the arterial puncture will be measured by the heart rate in beat per minute with a pulse oxymeter
Time frame: 1-minute postprocedural
Success of the arterial puncture
The arterial puncture will be measured as a success if the blood sample will be succeeded or as a failure : if the blood sample will be failed
Time frame: 1-minute postprocedural
Baseline anxiety measured with the HAD scale
The baseline anxiety will be measured at inclusion with the HAD scale (ranging from 0 to 21 points, with higher score correlating with more severe symptoms)
Time frame: Baseline
Time taken to perform the arterial puncture
the time of the blood sample will be noted
Time frame: Start and end time of the arterial puncture
Patient satisfaction or perception of the arterial puncture measured with a likert scale
The satisfaction will be assessed after the end of arterial puncture with a likert scale ("Are you satisfied with the care you received during the arterial puncture?: Strongly agree, Agree, Neither agree nor disagree, Disagree, Strongly disagree)
Time frame: 3-hour postprocedural
Situational anxiety measured by the heart rate
The situational anxiety experienced at the end of the arterial puncture will be measured by the heart rate in beat per minute with a pulse oxymeter
Time frame: Postprocedural
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
Of 111 non-industry phase 3 interventional studies under Pain, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 24 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Feb 2026 → Nov 2026, primary completion Feb 2026 → Nov 2028 and completion Nov 2029 → Nov 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.